Danes Are Crooning Over Novo Despite Drugmaker’s Share Slump
It’s been a painful couple of years for Denmark’s nearly 700,000-strong army of retail investors in Novo Nordisk A/S as the weight-loss drugmaker has lost market share to US rival Eli Lilly & Co.
Editorial & Syndication Notice: This story has been syndicated or published by 360 NEWS in accordance with verified fair-use, official press dissemination, and original attribution protocols. All trademarks, photos, and referenced quotes remain the property of their respective owners. For editorial corrections, press inquiries, or rights notices, contact [email protected].

